Document is current
Any future updates will be listed below
-
Authors
,
Kopp, Lisa M. http://orcid.org/0000-0002-3412-4189
Womer, Richard B.
Schwartz, Cindy L.
Ebb, David H.
Franco, Vivian I.
Hall, David
Barkauskas, Donald A.
Krailo, Mark D.
Grier, Holcombe E.
Meyers, Paul A.
Wexler, Leonard H.
Marina, Neyssa M.
Janeway, Katherine A.
Gorlick, Richard
Bernstein, Mark L.
Lipshultz, Steven E.
-
Funding
Funding for this research was provided by:
St. Baldrick's Foundation
QuadW Foundation
- License Information
-
More Information
Article History
Received: 3 July 2019
Accepted: 10 September 2019
First Online: 28 October 2019
Ethics approval and consent to participate
: Ethical approval was obtained from each institution's institutional review board (IRB) prior to the study (AOST0121 or P9754) opening for accrual. Written informed consent was obtained from children, adolescents, adults and/or their guardians according to local IRB guidelines before starting therapy.
: Not applicable.
: L.K. is an employee of the contract research organization Covance. M.K. is a consultant for Merck. K.J. has received travel reimbursement from Loxo oncology. R.G. has received laboratory research funding from Eisai. N.M. is an employee of Five Prime Therapeutics. P.M. has received travel reimbursement from Takeda and is a consultant for Eli Lilly and Astellas. S.L. is a consultant for Clinigen, a manufacturer of dexrazoxane, and Editor in Chief of Cardio-Oncology.
